Health Care & Life Sciences » Biotechnology | XBiotech Inc.

XBiotech Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
784.00
664.00
699.00
698.00
1,484.00
2,433
Gross Income
784.00
664.00
699.00
698.00
1,484.00
2,433
SG&A Expense
9,141.00
21,114.00
36,811.00
52,065.00
32,575.00
18,561
EBIT
9,925.00
21,778.00
37,510.00
52,763.00
34,059.00
20,994
Non Operating Income/Expense
3.00
53.00
27.00
47.00
555.00
544
Pretax Income
9,927.00
21,724.00
37,483.00
52,761.00
33,150.00
21,138
Consolidated Net Income
9,927.00
21,724.00
37,483.00
52,761.00
33,150.00
21,138
Net Income
9,927.00
21,724.00
37,483.00
52,761.00
33,150.00
21,138
Net Income After Extraordinaries
9,927.00
21,724.00
37,483.00
52,761.00
33,150.00
21,138
Net Income Available to Common
9,927.00
21,724.00
37,483.00
52,761.00
33,150.00
21,138
EPS (Basic)
0.45
0.90
1.22
1.63
0.95
0.59
Basic Shares Outstanding
22,220.40
24,162.70
30,802.00
32,403.40
34,875.80
35,804.30
EPS (Diluted)
0.45
0.90
1.22
1.63
0.95
0.59
Diluted Shares Outstanding
22,220.40
24,162.70
30,802.00
32,403.40
34,875.80
35,804.30
EBITDA
9,141.00
21,114.00
36,811.00
52,065.00
32,575.00
18,561
Non-Operating Interest Income
1.00
1.00
-
49.00
354.00
400

About XBiotech

View Profile
Address
5217 Winnebago Lane
Austin Texas 78744
United States
Employees -
Website http://www.xbiotech.com
Updated 07/08/2019
XBiotech, Inc. is a biopharmaceutical company, which engages in discovering and developing True Human monoclonal antibodies for treating diseases. It offers MABp1, which targets and neutralizes interleukin-1 alpha, a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue, and anxiety associated with advanced cancer. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.